𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia

✍ Scribed by Schlenk, R. F.; Dohner, H.

Book ID
125495096
Publisher
American Society of Hematology
Year
2013
Tongue
English
Weight
113 KB
Volume
2013
Category
Article
ISSN
1520-4391

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Treatment of acute myeloid leukemia in t
Treatment of acute myeloid leukemia in the elderly: A clinical dilemma
✍ Dr. J. A. Copplestone; A. G. Smith; C. Osmond; D. G. Oscier; T. J. Hamblin πŸ“‚ Article πŸ“… 1989 πŸ› John Wiley and Sons 🌐 English βš– 530 KB

Fifty-four patients representing all the cases of acute myeloid leukemia in patients aged over 60 years, presenting to three adjacent hospitals, were studied. Only 26 of the 54 patients were considered suitable for remission induction with intensive combination chemotherapy which produced seven comp

Progress in the treatment of acute myelo
Progress in the treatment of acute myeloid leukemia
✍ Farhad Ravandi; Alan K. Burnett; Edward D. Agura; Hagop M. Kantarjian πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 131 KB πŸ‘ 2 views

## Abstract Significant progress in understanding the mechanisms leading to the development of acute myeloid leukemia (AML) has led to the identification of numerous molecular abnormalities that may be responsible for leukemogenesis. Over the same period, large trials have established standard regi

Gemtuzumab ozogamicin in the treatment o
Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia
✍ Francis Giles; Elihu Estey; Susan O'Brien πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 484 KB πŸ‘ 2 views

## Abstract Gemtuzumab ozogamicin (GO) is a chemotherapeutic agent that consists of a humanized anti‐CD33 antibody (hP67.6) linked to N‐acetyl‐γ calicheamicin 1,2‐dimethyl hydrazine dichloride, a potent enediyne antitumor antibiotic. GO was approved conditionally by the Federal Drug Administration